T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Clinical trials for T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase trial tests a new approach for people with certain T-cell blood cancers (leukemia or lymphoma) that have returned. Researchers take a patient's own immune cells (or cells from a past stem cell donor), add a special receptor that targets a protein called CD5 found…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New immunotherapy combo aims to stop relapse in young blood cancer patients
Disease control Recruiting nowThis early-phase trial tests whether adding daratumumab (an immunotherapy drug) after a stem cell transplant can safely help control high-risk T-cell acute lymphoblastic leukemia or lymphoma in children, teens, and young adults up to age 39. About 30 participants will receive the…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 17, 2026 12:10 UTC
-
New universal CAR t therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
Engineered donor cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses specially trained immune cells from a healthy donor, designed to recognize and attack cancer cells carrying a marker called CD7. The goal is to see if t…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC